WellAir recently launched the Defend NV 400, an FDA-cleared Class II medical device that is 99.9% effective at inactivating airborne pathogens such as SARS-CoV-2 proxy virus (MS2 Bacteriophage) and MRSA, bacteria and fungi, and also purifies the air of particulate matter, volatile organic compounds, gases and odors.
The Defend NV 400 features WellAir’s unique, patented NanoStrike technology – a transformational method of air disinfection developed by a team of scientists and engineers, which bursts airborne pathogen cells, rapidly inactivating them to help ensure they are no longer a threat of infection. Unlike other technologies, NanoStrike’s effectiveness lies in its ability to inactivate nanosized pathogens on contact. The Defend NV 400’s four-stage pathogen inactivation and filtration process also utilizes medical-grade filters from Camfil to capture bacterial debris, fine and large particles, VOCs, gases, odors and impurities.
The Defend NV 400 is ideally suited for healthcare settings but is effective in a wide array of indoor environments, such as schools and offices.
The Defend NV 400 is available now. For more information, visit: https://www.wellairsolutions.com/